Transactions in Connection with Share Buy-back Program
03 Giugno 2024 - 3:09PM
Transactions in Connection with Share Buy-back Program
Company Announcement
COPENHAGEN, Denmark; June 3, 2024 – Genmab A/S (Nasdaq:
GMAB). On March 15, 2024, Genmab announced the initiation
of a share buy-back program to repurchase up to DKK 3.5 billion
worth of shares.The share buy-back program is expected to be
completed no later than December 16, 2024.
The following transactions were executed under the program from
May 27, 2024 to May 31, 2024:
|
|
Trading Platform |
No. of shares |
Average price (DKK) |
Total value (DKK) |
|
Accumulated through last
announcement |
|
799,099 |
|
1,609,560,257.36 |
|
May 27, 2024 |
XCSE |
32,495 |
1,952.69 |
|
|
|
CEUX |
13,714 |
1,953.29 |
|
|
|
AQEU |
2,518 |
1,953.34 |
|
|
|
TQEX |
2,224 |
1,953.39 |
|
|
|
Total |
50,951 |
1,952.91 |
99,502,788.74 |
|
May 28, 2024 |
XCSE |
30,244 |
1,957.87 |
|
|
|
CEUX |
13,418 |
1,961.65 |
|
|
|
AQEU |
1,744 |
1,957.51 |
|
|
|
TQEX |
1,994 |
1,957.75 |
|
|
|
Total |
47,400 |
1,958.92 |
92,852,992.86 |
|
May 29, 2024 |
XCSE |
26,429 |
1,924.99 |
|
|
|
CEUX |
13,040 |
1,924.24 |
|
|
|
AQEU |
1,484 |
1,925.96 |
|
|
|
TQEX |
2,070 |
1,924.34 |
|
|
|
Total |
43,023 |
1,924.76 |
82,809,104.36 |
|
May 30, 2024 |
XCSE |
31,371 |
1,922.78 |
|
|
|
CEUX |
13,210 |
1,916.59 |
|
|
|
AQEU |
2,202 |
1,922.60 |
|
|
|
TQEX |
2,143 |
1,916.71 |
|
|
|
Total |
48,926 |
1,920.83 |
93,978,729.18 |
|
May 31, 2024 |
XCSE |
25,286 |
1,932.26 |
|
|
|
CEUX |
13,373 |
1,929.83 |
|
|
|
AQEU |
2,286 |
1,929.50 |
|
|
|
TQEX |
2,077 |
1,929.51 |
|
|
|
Total |
43,022 |
1,931.22 |
83,085,136.14 |
|
Total |
|
233,322 |
|
452,228,751.28 |
|
Accumulated under the program |
|
1,032,421 |
|
2,061,789,008.64 |
| |
|
|
|
|
|
Details of each transaction are included as an appendix to this
announcement.
Following these transactions, Genmab holds 1,881,559 shares as
treasury shares, corresponding to 2.85% of the total share capital
and voting rights.
The share buy-back program is undertaken in accordance with
Regulation (EU) No. 596/2014 (‘MAR’) and the Commission Delegated
Regulation (EU) 2016/1052, also referred to as the “Safe Harbour
Regulation.” Further details on the terms of the share buy-back
program can be found in our company announcement no. 22 dated March
15, 2024.
About Genmab Genmab is an international
biotechnology company with a core purpose guiding its unstoppable
team to strive towards improving the lives of patients through
innovative and differentiated antibody therapeutics. For 25 years,
its passionate, innovative and collaborative team has invented
next-generation antibody technology platforms and leveraged
translational, quantitative, and data sciences, resulting in a
proprietary pipeline including bispecific T-cell engagers,
next-generation immune checkpoint modulators, effector function
enhanced antibodies, and antibody-drug conjugates. To help develop
and deliver novel antibody therapies to patients, Genmab has formed
20+ strategic partnerships with biotechnology and pharmaceutical
companies. By 2030, Genmab’s vision is to transform the lives of
people with cancer and other serious diseases with
knock-your-socks-off (KYSO®) antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen,
Denmark, with international presence across North America, Europe
and Asia Pacific. For more information, please
visit Genmab.com and follow us on LinkedIn and X.
Contact:
Marisol Peron, Senior Vice President, Global Communications &
Corporate AffairsT: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor RelationsT: +45
3377 9558; E: acn@genmab.com
This Company Announcement contains forward looking statements.
The words “believe,” “expect,” “anticipate,” “intend” and “plan”
and similar expressions identify forward looking statements. Actual
results or performance may differ materially from any future
results or performance expressed or implied by such statements. The
important factors that could cause our actual results or
performance to differ materially include, among others, risks
associated with pre-clinical and clinical development of products,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products or technologies obsolete, and other factors. For a further
discussion of these risks, please refer to the risk management
sections in Genmab’s most recent financial reports, which are
available on www.genmab.com and the risk factors included in
Genmab’s most recent Annual Report on Form 20-F and other filings
with the U.S. Securities and Exchange Commission (SEC), which are
available at www.sec.gov. Genmab does not undertake any obligation
to update or revise forward looking statements in this Company
Announcement nor to confirm such statements to reflect subsequent
events or circumstances after the date made or in relation to
actual results, unless required by law. Genmab A/S and/or its
subsidiaries own the following trademarks: Genmab®; the Y-shaped
Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®;
HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®.
Company Announcement no. 40 CVR no. 2102 3884 LEI Code
529900MTJPDPE4MHJ122
Genmab A/SCarl Jacobsens Vej 302500 Valby Denmark
- 240603_CA40_Transactions in connection with SBBP
- 240603_Appendix_SBBP Transactions May 27-31
Grafico Azioni Genmab AS (TG:GE9)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Genmab AS (TG:GE9)
Storico
Da Nov 2023 a Nov 2024
